Figure 1. Evolution from autologous to off-the-shelf cell therapy. Comparison of autologous and allogeneic cell therapy manufacturing workflows. Unlike patient-specific manufacturing, iPSC-derived allogeneic therapies leverage Master Cell Banks (MCBs), standardized manufacturing processes, and large-scale production to enable scalable, off-the-shelf regenerative medicine. Executive Summary Key Takeaways Induced pluripotent stem cells (iPSCs) have evolved from a stem cell tech

Figure 1. The Journey of Induced Pluripotent Stem Cells (iPSCs): From Somatic Cell Reprogramming to Regenerative Medicine. Adult somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs), expanded and banked, differentiated into specialized cell types, and applied in disease modeling, drug discovery, regenerative medicine, and cell therapy. This workflow highlights how iPSCs serve as a foundational platform technology connecting basic research with transla